Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 4 | -$2.00 | -$0.87 | -$1.25 |
Q2 2024 | 7 | -$3.24 | -$1.41 | -$2.02 |
Q3 2024 | 5 | -$2.45 | -$1.07 | -$1.53 |
Q4 2024 | 11 | -$0.47 | $2.76 | $0.47 |
Q1 2025 | 5 | -$2.07 | -$1.10 | -$1.72 |
Q2 2025 | 2 | -$3.41 | -$1.49 | -$2.13 |
Q3 2025 | 2 | $0.10 | $0.23 | $0.15 |
Q4 2025 | 2 | $0.21 | $0.49 | $0.30 |
Q1 2026 | 1 | -$7.21 | -$3.14 | -$4.49 |
BioNTech SE last posted its earnings results on Monday, November 4th, 2024. The company reported $0.868 earnings per share for the quarter, topping analysts' consensus estimates of $-1.67166 by $2.53966. The company had revenue of 1.24 B for the quarter and had revenue of 3.82 B for the year. BioNTech SE has generated $4 earnings per share over the last year ($3.83 diluted earnings per share) and currently has a price-to-earnings ratio of -54.05. BioNTech SE has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/04/2024 | Q3 2024 | -$1.67 | $0.83 | 2.5 | $572.38 M | $1.24 B |
08/05/2024 | Q2 2024 | -$2.16 | -$3.36 | -1.2 | $144.58 M | $128.70 M |
05/06/2024 | Q1 2024 | -$0.82 | -$1.31 | -0.49 | $187.60 M | |
11/06/2023 | Q4 2023 | -$0.11 | $1.88 | 1.99 | $1.48 B | |
08/07/2023 | Q3 2023 | -$0.75 | $0.69 | 1.44 | $899.06 M | $895.30 M |
05/08/2023 | Q2 2023 | $0.15 | -$0.79 | -0.94 | $685.12 M | $167.70 M |
05/08/2023 | Q1 2023 | $0.15 | $2.05 | 1.9 | $1.28 B | |
11/07/2022 | Q4 2022 | $4.61 | $8.94 | 4.33 | $4.28 B | |
11/07/2022 | Q3 2022 | $4.61 | $6.98 | 2.37 | $2.02 B | $3.46 B |
05/09/2022 | Q2 2022 | $9.65 | $6.45 | -3.2 | $4.07 B | $3.20 B |
03/30/2022 | Q1 2022 | $8.23 | $14.24 | 6.01 | $6.37 B | |
11/09/2021 | Q4 2021 | $12.62 | $12.98 | 0.36 | $5.53 B | |
08/09/2021 | Q3 2021 | $8.91 | $13.14 | 4.23 | $5.90 B | $6.09 B |
05/10/2021 | Q2 2021 | $3.74 | $11.42 | 7.68 | $3.86 B | $5.31 B |
03/30/2021 | Q1 2021 | -$0.18 | $4.64 | 4.82 | $2.05 B | |
11/10/2020 | Q4 2020 | -$0.46 | $1.56 | 2.02 | $345.44 M | |
08/11/2020 | Q3 2020 | -$0.29 | -$0.88 | -0.59 | $60.40 M | $67.46 M |
03/31/2020 | Q2 2020 | -$0.19 | -$0.38 | -0.19 | $95.00 M | $41.76 M |
03/31/2020 | Q1 2020 | -$0.19 | -$0.24 | -0.05 | $27.66 M | |
03/31/2020 | Q4 2019 | -$0.19 | -$0.28 | -0.09 | $27.99 M |
BioNTech SE has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates.
In the previous quarter, BioNTech SE (:BNTX) reported $0.868 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.67166 by $2.53966.
The conference call for BioNTech SE's latest earnings report can be listened to online.
The conference call transcript for BioNTech SE's latest earnings report can be read online.
BioNTech SE (:BNTX) has a recorded annual revenue of $3.82 B.
BioNTech SE (:BNTX) has a recorded net income of $3.82 B. BioNTech SE has generated $3.83 earnings per share over the last four quarters.
BioNTech SE (:BNTX) has a price-to-earnings ratio of -54.05 and price/earnings-to-growth ratio is -8.38.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED